Last updated on November 2019

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC


Brief description of study

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Clinical Study Identifier: NCT03052608

Find a site near you

Start Over

Florida Cancer Specialists

Altamonte Springs, FL United States
  Connect »

Florida Cancer Specialists

Brandon, FL United States
  Connect »

Florida Cancer Specialists

Clearwater, FL United States
  Connect »

Florida Cancer Specialists

Gainesville, FL United States
  Connect »

Florida Cancer Specialists

Lecanto, FL United States
  Connect »

Florida Cancer Specialists

New Port Richey, FL United States
  Connect »

Florida Cancer Specialists

Orange City, FL United States
  Connect »

Florida Cancer Specialists

Orlando, FL United States
  Connect »

Florida Cancer Specialists

Saint Petersburg, FL United States
  Connect »

Florida Cancer Specialists

Spring Hill, FL United States
  Connect »

Florida Cancer Specialists

Tavares, FL United States
  Connect »

Florida Cancer Specialists

The Villages, FL United States
  Connect »

Florida Cancer Specialists

Winter Park, FL United States
  Connect »

Tennessee Oncology, PLLC

Dickson, TN United States
  Connect »

Tennessee Oncology, PLLC

Franklin, TN United States
  Connect »

Tennessee Oncology, PLLC

Gallatin, TN United States
  Connect »

Tennessee Oncology, PLLC

Hermitage, TN United States
  Connect »

Tennessee Oncology, PLLC

Lebanon, TN United States
  Connect »

Tennessee Oncology, PLLC

Murfreesboro, TN United States
  Connect »

Tennessee Oncology, PLLC

Nashville, TN United States
  Connect »

Tennessee Oncology, PLLC

Shelbyville, TN United States
  Connect »

Tennessee Oncology, PLLC

Smyrna, TN United States
  Connect »

Institut Paoli-Calmettes

Marseille cedex 09, France
  Connect »

H pital Nord

Marseille cedex 20, France
  Connect »

Service Ophtalmologie

Marseille cedex 20, France
  Connect »

Hopital Foch

Suresnes, France
  Connect »

H pital Larrey

Toulouse cedex 9, France
  Connect »

lnstitut Claudius Regaud

Toulouse cedex 9, France
  Connect »

Tuen Mun Hospital

Hong Kong, Hong Kong
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Ulsan University Hospital

Ulsan, Korea, Republic of
  Connect »

RBHI Kursk Regional Clinical Oncology Dispensary

Kislino, Ryshkovsky Rural Council, Russian Federation
  Connect »

Raffles Hospital

Singapore, Singapore
  Connect »